Key Developments For Abaxis Inc
Abaxis Inc (ABAX.O) (Nasdaq)
Abaxis, Inc. Announces Launch of Fully Automated Canine Wellness Profile That Includes A Canine Heartworm Antigen Test
Abaxis, Inc. announced that it has received USDA approval for its Canine Heartworm Antigen Test to be performed on the company's VetScan VS2 fully automated instrument. The Heartworm assay is now performed in the instrument alongside and simultaneously with eleven other important Canine health determinations, providing reliable results in minutes, at the point-of-care, and from only two drops of whole blood.
Abaxis, Inc. Realigns North American Medical Sales And Marketing
Abaxis, Inc. announced a reorganization of its North American sales and marketing organization resulting from a strategic review of the Company's medical business.
Abaxis, Inc. Announces Launch Of Two New Products
Abaxis, Inc. announced that it will launch the VetScan VSpro Coagulation Analyzer and VetScan Canine Heartworm Rapid Test at the North American Veterinary Conference in Orlando, Florida on January 18, 2009.
Abaxis, Inc. Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
Abaxis, Inc. announced that it has signed an agreement with S.A. Scientific for the manufacturing of a Canine Heartworm Lateral Flow / Rapid Test Kit.
Abaxis, Inc. Announces Worldwide Animal Health Licensing Agreement For Rapid Test Technology
Abaxis, Inc. announced that it has entered into a license agreement for co exclusive worldwide rights in the field of animal health diagnostics in the professional marketplace for certain technologies pertaining to lateral flow immunoassay devices and methods. This license agreement provides Abaxis the co exclusive opportunity to utilize these technologies to expand the Abaxis product portfolio and enter on a large scale the professional veterinary rapid diagnostic market. This includes point of care tests for infectious diseases, hormones and therapeutic drugs.
